OpenArc Corporate Advisory’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
OpenArc Corporate Advisory's VRTX Position: Q2 2026 in Review
OpenArc Corporate Advisory increased its Vertex Pharmaceuticals (VRTX) stake by 0.08% in Q2 2026, buying an estimated $886 and bringing the position to 2,397 shares worth $1.19M. The position accounts for 0.01% of the portfolio, ranked #314.
OpenArc Corporate Advisory first reported a position in VRTX in Q4 2025 and has held it in 3 quarters since. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- OpenArc Corporate Advisory held 2,397 shares of Vertex Pharmaceuticals worth $1.19M as of Q2 2026.
- OpenArc Corporate Advisory bought 2 Vertex Pharmaceuticals shares in Q2 2026, an estimated $886.
- Vertex Pharmaceuticals made up 0.01% of OpenArc Corporate Advisory's portfolio in Q2 2026, its #314 holding.
- OpenArc Corporate Advisory first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
- 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on OpenArc Corporate Advisory's 13F filing for Q2 2026, filed 5 Aug 2026.